ArticleInternational journal of general medicine2025
MCU-Mediated SIRT3 Inhibition Drives Oxidative Stress-Induced Cytoskeletal Disruption in Pancreatic Ductal Epithelium: A Mechanism of Hypertriglyceridemic Acute Pancreatitis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond triglyceride clearance: rethinking hypertriglyceridemia-associated acute pancreatitis in the apoC-III era.Gastroenterology report · 2026Review
Corrections and comments
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The pathogenesis of hypertriglyceridemia -induced pancreatitis (HTGP) is complex and not fully understood. The purpose of this study was to investigate the molecular mechanism of the mitochondrial Ca Methods: We observed the expression levels of MCU and silent information regulator 3 (SIRT3) in both in vivo and in vitro HTGP models, and after intervention with ruthenium red (RR), an active inhibitor of MCU, and 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP), an active inhibitor of SIRT3, changes in mitochondrial calcium ions, oxidative stress-related indices, the microfilament cytoskeleton, and monolayer cell permeability were detected. Results: In vivo and in vitro experiments revealed the upregulation of MCU and downregulation of SIRT3 in caerulein-treated HPDE6-C7 cells and mice, along with increased mitochondrial calcium accumulation, increased reactive oxygen species (ROS) and malondialdehyde (MDA) levels, decreased gamma-glutamylcysteine (GSH) levels, destruction of the microfilament cytoskeleton, and increased monolayer permeability. During in vitro experiments, intervention with RR, an active inhibitor of MCU, reversed the above changes, whereas intervention with 3-TYP, an active inhibitor of SIRT3, further exacerbated the above changes. Conclusion: MCU may be involved in the pathogenesis of AP by inhibiting the expression of SIRT3, resulting in increased oxidative stress and destruction of the microfilament cytoskeleton and pancreatic ductal mucosal barrier (PDMB) functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.